What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Antibody
His primary scientific interests are in Molecular biology, Haematopoiesis, Immunology, Cellular differentiation and Progenitor cell.
His Molecular biology research includes elements of Myeloid, Methylation, CRISPR and Autologous transplantation.
As part of his Stem cell and Cell biology and Haematopoiesis studies, Marcus O. Muench is studying Haematopoiesis.
He has researched Stem cell in several fields, including Fms-Like Tyrosine Kinase 3, ROR1, Tropomyosin receptor kinase C, Platelet-derived growth factor receptor and Receptor tyrosine kinase.
The Cellular differentiation study combines topics in areas such as Natural killer cell, T lymphocyte, Clonogenic assay and Sialyltransferase.
His Progenitor cell study combines topics from a wide range of disciplines, such as Immune system and Glycan.
His most cited work include:
- Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. (612 citations)
- Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs (414 citations)
- Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac (302 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Haematopoiesis, Stem cell, Molecular biology and Progenitor cell.
His Immunology research incorporates elements of Fetus, Ex vivo and Transplantation.
His study in the field of Stem cell factor is also linked to topics like Population.
His studies deal with areas such as Blood cell and Cancer research as well as Stem cell.
His research in Molecular biology focuses on subjects like Methylation, which are connected to Epigenetics.
Marcus O. Muench interconnects Endocrinology and Internal medicine in the investigation of issues within Progenitor cell.
He most often published in these fields:
- Immunology (54.29%)
- Haematopoiesis (45.14%)
- Stem cell (39.43%)
What were the highlights of his more recent work (between 2017-2021)?
- Virology (28.00%)
- Antibody (17.14%)
- In vivo (9.14%)
In recent papers he was focusing on the following fields of study:
Marcus O. Muench mainly investigates Virology, Antibody, In vivo, Flow cytometry and Platelet.
His study in the field of Tissue tropism also crosses realms of Attenuated vaccine.
His studies in In vivo integrate themes in fields like Apoptosis, In vitro and Immune system, Immune tolerance.
His Flow cytometry study improves the overall literature in Molecular biology.
His Platelet study is concerned with the field of Immunology as a whole.
His Immunology study frequently draws connections between related disciplines such as Ex vivo.
Between 2017 and 2021, his most popular works were:
- Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. (29 citations)
- Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. (29 citations)
- Diverse progenitor cells preserve salivary gland ductal architecture after radiation-induced damage. (22 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Antibody
Marcus O. Muench spends much of his time researching Salivary gland, Cell biology, Stem cell, Progenitor cell and Myoepithelial cell.
The concepts of his Salivary gland study are interwoven with issues in Ductal cells, Intercalated duct, Progenitor and Cellular differentiation.
His Cell biology study focuses mostly on Haematopoiesis and Cell therapy.
His research on Stem cell often connects related topics like Myeloid.
His research in Myoepithelial cell intersects with topics in CD34, CD90, Mesenchymal stem cell and Salivary Gland Disorder.
CD90 connects with themes related to Stromal cell in his study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
